4-{3-[(1R)-((S)-tert-butanesulfinylamino)-3-methylbutyl]-6-methyl-2-pyridinyl}-1-piperazinecarboxylic acid tert-butyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-{3-[(1R)-((S)-tert-butanesulfinylamino)-3-methylbutyl]-6-methyl-2-pyridinyl}-1-piperazinecarboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-[3-[(1R)-1-[[(S)-tert-butylsulfinyl]amino]-3-methylbutyl]-6-methylpyridin-2-yl]piperazine-1-carboxylate
• 化学式: C₂₄H₄₂N₄O₃S
• 分子量: 466.688
• InChiKey: KNOSQRDZCCATSV-CGKQSPDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  94
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-{3-[(1R)-((S)-tert-butanesulfinylamino)-3-methylbutyl]-6-methyl-2-pyridinyl}-1-piperazinecarboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Design, Synthesis, In Vitro, and In Vivo Characterization of Phenylpiperazines and Pyridinylpiperazines as Potent and Selective Antagonists of the Melanocortin-4 Receptor

  摘要：

  Benzylamine and pyridinemethylamine derivatives were synthesized and characterized as potent and selective antagonists of the melanocortin-4 receptor (MC4R). These compounds were also profiled in rodents for their pharmacokinetic properties. Two compounds with diversified profiles in chemical structure, pharmacological activities, and pharmacokinetics, 10 and 12b, showed efficacy in an established murine cachexia model. For example, 12b had a K-i value of 3.4 nM at MC4R, was more than 200-fold selective over MC3R, and had a good pharmacokinetic profile in mice, including high brain penetration. Moreover, 12b was able to stimulate food intake in the tumor-bearing mice and reverse their lean body mass loss. Our results provided further evidence that a potent and selective MC4R antagonist with appropriate pharmacokinetic properties might potentially be useful for the treatment of cancer cachexia.

  DOI：

  10.1021/jm701137s
• 作为产物：
  描述：

  tert-butyl 4-[3-[(E)-[(S)-tert-butylsulfinyl]iminomethyl]-6-methylpyridin-2-yl]piperazine-1-carboxylate 、 (2-methylpropyl)lithium 在 三甲基铝 作用下， 以 四氢呋喃 为溶剂， 生成 4-{3-[(1R)-((S)-tert-butanesulfinylamino)-3-methylbutyl]-6-methyl-2-pyridinyl}-1-piperazinecarboxylic acid tert-butyl ester
  参考文献：
  名称：

  Design, Synthesis, In Vitro, and In Vivo Characterization of Phenylpiperazines and Pyridinylpiperazines as Potent and Selective Antagonists of the Melanocortin-4 Receptor

  摘要：

  Benzylamine and pyridinemethylamine derivatives were synthesized and characterized as potent and selective antagonists of the melanocortin-4 receptor (MC4R). These compounds were also profiled in rodents for their pharmacokinetic properties. Two compounds with diversified profiles in chemical structure, pharmacological activities, and pharmacokinetics, 10 and 12b, showed efficacy in an established murine cachexia model. For example, 12b had a K-i value of 3.4 nM at MC4R, was more than 200-fold selective over MC3R, and had a good pharmacokinetic profile in mice, including high brain penetration. Moreover, 12b was able to stimulate food intake in the tumor-bearing mice and reverse their lean body mass loss. Our results provided further evidence that a potent and selective MC4R antagonist with appropriate pharmacokinetic properties might potentially be useful for the treatment of cancer cachexia.

  DOI：

  10.1021/jm701137s

文献信息

• Design, Synthesis, In Vitro, and In Vivo Characterization of Phenylpiperazines and Pyridinylpiperazines as Potent and Selective Antagonists of the Melanocortin-4 Receptor
  作者：Joe A. Tran、Wanlong Jiang、Fabio C. Tucci、Beth A. Fleck、Jenny Wen、Yang Sai、Ajay Madan、Ta Kung Chen、Stacy Markison、Alan C. Foster、Sam R. Hoare、Daniel Marks、John Harman、Caroline W. Chen、Melissa Arellano、Dragan Marinkovic、Haig Bozigian、John Saunders、Chen Chen

  DOI：10.1021/jm701137s

  日期：2007.12.13

  Benzylamine and pyridinemethylamine derivatives were synthesized and characterized as potent and selective antagonists of the melanocortin-4 receptor (MC4R). These compounds were also profiled in rodents for their pharmacokinetic properties. Two compounds with diversified profiles in chemical structure, pharmacological activities, and pharmacokinetics, 10 and 12b, showed efficacy in an established murine cachexia model. For example, 12b had a K-i value of 3.4 nM at MC4R, was more than 200-fold selective over MC3R, and had a good pharmacokinetic profile in mice, including high brain penetration. Moreover, 12b was able to stimulate food intake in the tumor-bearing mice and reverse their lean body mass loss. Our results provided further evidence that a potent and selective MC4R antagonist with appropriate pharmacokinetic properties might potentially be useful for the treatment of cancer cachexia.